Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Résumé détaillé
One of these mRNA pioneers has the products and pipeline to drive growth.
The coronavirus pandemic turned two little-known mRNA companies into household names. Moderna (MRNA +1.29%) and BioNTech (BNTX -2.26%) brought their vaccines to market, collected billions of dollars in revenue, and then watched demand fade in recent years. Both stocks fell significantly from their highs, and both companies have spent the past few years trying to prove they're more than coronavirus vaccine makers.
This year, their paths have diverged. Moderna's stock has soared as investors rushed to bet on the company's promising personalized cancer vaccine program. BioNTech, meanwhile, saw its stock price slip and prepared to say goodbye to its founders.
So, heading into 2027, which of these mRNA pioneers is the better buy?
First, a quick recap. Both companies have faced the same problem: the coronavirus vaccine was a windfall that couldn't last. Moderna's product sales peaked at more than $18 billion in 2022, and BioNTech's reached a high of about the same level in 2021. Each responded by cutting costs and shifting toward oncology. BioNTech has more than 25 phase 2 and phase 3 clinical trials ongoing in that treatment area. Moderna's personalized cancer vaccine candidate, intismeran autogene, is involved in four phase 3 trials and several earlier-stage trials.
BioNTech has real strengths. It has more than $17 billion in cash and investments, and its lead candidate, pumitamig, is a bispecific antibody it's developing with Bristol Myers Squibb. The company is evaluating pumitamig in seven global pivotal studies across several cancer types. Meanwhile, BioNTech recently had mixed results in a phase 3 trial of an antibody-drug conjugate with DualityBio. Though the candidate met its primary endpoint, its impact may be "limited," the companies said.
The coronavirus vaccine remains BioNTech's only commercialized product for the moment as we wait for the pipeline to potentially produce others.
Moderna, by contrast, has several commercialized products.
Début de l'article, extrait de The Motley Fool. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)



